World Library  
Flag as Inappropriate
Email this Article

Anti-transglutaminase antibodies

Article Id: WHEBN0012519106
Reproduction Date:

Title: Anti-transglutaminase antibodies  
Author: World Heritage Encyclopedia
Language: English
Subject: ATA, Coeliac disease, Malabsorption, Transglutaminase, Autoantibody, Tissue transglutaminase
Collection:
Publisher: World Heritage Encyclopedia
Publication
Date:
 

Anti-transglutaminase antibodies

Autoantibody
Anti-transglutaminase
Common autoantibody characteristics
Autoantibody class IgA, IgG
DQ2.5
HLA associations DQ8
DQ2.2/DQ7.5
Associated T-Cell
restrictions
DQ/gliadin, DQ/deamidated-gliadin
Triggering
agent(s)
Triticeae glutens(Prolamins and Glutelins)
Isoform specific
autoantibody characteristics
Autoantigen
Isoform
Tissue transglutaminase
Autoantigen Gene TGM2
Affected Organ(s) Intestine (small)
Affected Tissue(s) Villi
Affected Cells(s) Epithelial Cells
Also Affected Epithelial matrix
Associated
Disease(s)
Coeliac disease
Triggering
agent
& Gastrointestinal viruses
Autoantigen
Isoform
Epidermal transglutaminase
Autoantigen Gene TGM3
Affected Organ(s) Skin
Associated
Disease(s)
Dermatitis herpetiformis


Anti-transglutaminase antibodies (ATA) are autoantibodies against the transglutaminase protein. Antibodies serve an important role in the immune system by detecting cells and substances that the rest of the immune system then eliminates. These cells and substance can be foreign (for example, viruses) and also can be produced by the body (for example, cancer cells). Antibodies against the body's own products are called autoantibodies. Autoantibodies can sometimes errantly be directed against healthy portions of the organism, causing autoimmune diseases.

ATA can be classified according to 2 different schemes: transglutaminase isoform and immunoglobulin reactivity subclass (IgA, IgG) toward transglutaminases.

Transglutaminase isoform reactivity


Anti-tissue transglutaminase

Antibodies to tissue transglutaminase (ATA or anti-tTG) are found in patients with several conditions, including coeliac disease, juvenile diabetes,[1] inflammatory bowel disease,[2] and various forms of arthritis.[3][4]

In Coeliac Disease, ATA are involved in the destruction of the villous extracellular matrix and target the destruction of intestinal villous epithelial cells by killer cells. Deposits of anti-tTG in the intestinal epithelium predict coeliac disease.[5]

Anti-endomysial reactivity

The endomysium is a layer of connective tissue that ensheaths a muscle fiber. The endomysium contains a form of transglutaminase called "tissue transglutaminase" or "tTG" for short, and antibodies that bind to this form of transglutaminase are called anti-endomysial antibodies (EMA). [6] The antiendomysial antibody test is a histological assay for patient serum binding to esophageal tissue from primate. EMA are present in celiac disease. They do not cause any direct symptoms to muscles, but detection of EMA is useful in the diagnosis of the disease.[7]

Anti-epidermal transglutaminase

Antibodies to epidermal transglutaminase (eTG, also keratinocyte transglutaminase) are the autoantibodies believed to cause dermatitis herpetiformis.[8]

Immunoglobin subclass

ATA IgA are more frequently found in Celiac Disease (CD); however, ATA IgG are found in CD and at higher levels when affected individual had the IgA-less phenotype. The IgA-less phenotype is more common in CD than the normal population; however, one haplotype, DQ2.5 is found in most CD, has genetic linkage to the IgA-less gene location.

Associated Conditions

Celiac Disease

Most attention to anti-transglutaminase antibodies is given with respect to Celiac Disease. A recent study of children published in 2007 demonstrated that the level of ATA in correlates with the scalar Marsh score for the disease in the same patient.[9] See the Coeliac wiki article for more information.

High levels (titers) of ATA are found in almost all instances of coeliac disease.[10] Given the association of ATA with coeliac disease, and the prevalence of the latter, it is estimated that ~1% of the population have potentially pathogenic levels of ATA.

Inflammatory bowel disease

A study published in Nature in 2001 found high levels of anti-transglutaminase antibodies in Inflammatory Bowel Disease - specifically in Crohn's Disease and Ulcerative rectocolitis.[2]

Arthritis

Studies of patients with various forms of arthritis showed highly increased frequencies of antibodies against guinea pig transglutaminase, human recombinant transglutaminase and peptidylarginine deiminase type 4 (PAD4). This suggests a potential for crossreactive antibodies between anti-tTG and anti-PAD4.[11]

Juvenile diabetes and anti-tTG

Childhood (male) Type 1 diabetes (T1D) increases the risk for CD and vice versa[12] and the early signs of CD may precede T1D in many cases.[13] A search for CD in juvenile diabates patients revealed that GF diet resulted in some improvements.[14] A elevated number of diabetes patients have ATA[15] along with increased numbers of gluten-specific T-cells.

Asymptomatic ATA+

A recent screening[16] of 7550 Briton's found 87 undetected ATA+. In this study a 50% increase of ATA was associated with:

Similar studies

  • increased mortality, particularly to cancer[17]

Symptomatic ATA+

Alcohol consumption

ATA correlated with biomarkers of alcohol consumption, proinflammatory cytokines and markers of fibrogenesis.[20]

Mechanism of Autoimmunity

The antibodies to tissue transglutaminase follow a complex pathway of generation. For most antigens, T-cells specific to those antigens develop; for autoimmunity, either autoreactive T-cells are not suppressed, or antigens escape the protective process. T-cells are stimulated by antigen, presented by MHC molecules (HLA in humans) on antigen-reactive B-cells. These T-helper cells then stimulate B-cells to multiply and mature into plasma cells that make IgG to that protein.

In the case of coeliac disease, the current understanding is that tTG autoimmunity arises when T-cells are generated against wheat gliadin and similar gluten proteins made by a class of grasses called Triticeae, which includes wheat (See Wheat taxonomy), barley, and rye. The T-cells are defined by the ability to react to HLA-DQ8 and DQ2.5 restricted antigens and gliadin is one of the antigens. Gliadin is a favored dietary substrate for transglutaminase because of many enzyme reaction sites on gliadin. In disease, transglutaminase reacts with gliadin forming a linkage.[21] In forming this bond transglutaminase becomes linked to T-cell epitopes on gliadin. B-cells with surface IgM that react to transglutaminase can present it with bound gliadin peptides to T-cells which stimulate B-cell maturation and proliferation to plasma cells making IgA or IgM.

ATA changes the behavior of tTG. Some studies have revealed that antibodies increase the activity of tTG, instead of inhibiting activity as is commonly encountered with function-altering antibodies. A recent study has shown that ATA also modify and increase replication in intestinal epithelial cells, by apparently interacting with cell-surface transglutaminase.[22]

Links

  • Anti-Tissue Transglutaminase (tTG) Antibodies Also Found in Inflammatory Bowel Disease
  • Tg6 Antibody Plays a Key Role in Celiac-Related Neurological Disorders Celiac.com 09/02/2008

References

This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and USA.gov, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for USA.gov and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
 
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
 
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.
 


Copyright © World Library Foundation. All rights reserved. eBooks from Project Gutenberg are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.